In the present work, the concentrations of Ab11-x and Ab17-x peptides (x ¼ 40 or 42), which result from the combined cleavages of b-amyloid precursor protein (AbPP) by b'/a or a/c-secretases, respectively, were assessed in cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI). Specific multiplexed assays were set up using new anti-40 and anti-42 monoclonal antibodies (mAbs) for the capture of these N-truncated Ab peptides and anti-11 or anti-17 mAbs for their detection. The specificity, sensitivity and reproducibility of such assays were assessed using synthetic peptides and human cell models. Ab11-x and Ab17-x were then measured in CSF samples from patients with AD (n ¼ 23), MCI (n ¼ 23) and controls with normal cognition (n ¼ 21). Ab11-x levels were significantly lower in patients with MCI than in controls. Compared with the combined quantification of Ab1-42, total Tau (T-Tau) and phosphorylated Tau (P-Tau; AlzBio3, Innogenetics), the association of Ab11-40, Ab17-40 and T-Tau improved the discrimination between MCI and controls. Furthermore, when patients with MCI were classified into two subgroups (MCI p1.5 or X2 based on their CDR-SB (Cognitive Dementia Rating-Sum of Boxes) score), the CSF Ab17-40/Ab11-40 ratio was significantly higher in patients with CDR-SB p1.5 than in controls, whereas neither Ab1-42, T-Tau nor P-Tau allowed the detection of this subpopulation. These results need to be confirmed in a larger clinical prospective cohort.
Introduction
Alzheimer's disease (AD) is the most common form of dementia and is characterized by loss of memory and progressive cognitive impairment. The major histopathological hallmarks of AD are extracellular senile plaques, which mainly consist of b-amyloid peptides (Ab), 1 and intracellular neurofibrillary tangles, which are mostly composed of hyperphosphorylated microtubule-associated Tau protein. 2, 3 Accumulation of Ab peptide aggregates could lead to hippocampal synaptic dysfunction, 4 thereby explaining the AD memory deficits. Episodic memory loss is generally considered as the core requirement for the diagnosis of mild cognitive impairment (MCI). 5, 6 Early and reliable AD diagnosis at the stage of MCI would improve AD prognosis and provide the means to examine the putative efficacy of newly designed drugs as disease modifiers. Today, the combined measurement of total Tau (T-Tau), phosphorylated Tau (P-Tau) and Ab1-42 in cerebrospinal fluid (CSF) allows the best biochemical characterization of the patients' clinical status, even from a prognostic point of view. [7] [8] [9] [10] [11] [12] However, despite their good diagnostic performance, we clearly need complementary biomarkers to differentiate between AD and non-AD disorders, [13] [14] [15] particularly at early stages (MCI). In normal conditions, the b-amyloid precursor protein (AbPP) mainly undergoes a nonamyloidogenic cleavage by a-secretase activity that precludes Ab generation. 16 Conversely, in the amyloidogenic pathway, AbPP is sequentially cleaved by the b-secretase BACE1 and by the g-secretase proteolytic complex to produce various Ab peptides, including the full-length (fl) species Ab1-40 and Ab1-42. 16, 17 Besides flAb peptides, many N-and C-terminally truncated variants have also been identified and isolated from cell supernatants, animal models and brain extracts from patients with AD, [18] [19] [20] [21] [22] and they could have escaped immunodetection in the CSF because of technical limitations. This is not anecdotal as within this plethoric Ab-linked peptidome, several Ab truncated variants could have physiopathological and diagnostic relevance. For instance, N-truncated peptides at residue 11 of flAb (Ab11-x) results from BACE1-mediated b'-cleavage 23 and might be seen as an indicator of b-secretase-associated AbPP processing that could happen in pathological conditions. 24 Ab17-x variants result from a-secretase activity and could also be revelatory of a pathological situation, because a-secretase activity is apparently downregulated in AD. [25] [26] [27] [28] Here, to evaluate Ab11-x and Ab17-x levels in complex fluids, including human CSF, we describe new specific multiplexed assays based on the capture of the different Ab peptides by new specific anti-C-terminal (Cter) monoclonal antibodies (mAbs; 6H7 anti-40 antibody and 12E8 anti-42 antibody) and their detection by very specific anti-N-terminal 24 We then assessed the ability of these assays to monitor CSF Ab11-x and Ab17-x levels at very early AD stages and show that, unlike the currently used assays, the Ab17-40/Ab11-40 ratio allows discriminating between patients with very early MCI and controls. Although the number of patients was limited, our study indicates that additional N-truncated Ab-related fragments could be used as biomarkers of AD pathology onset.
Materials and methods
Peptide synthesis. The immunogenic peptide C-KKKGSAb33-42 used for the production of the anti-42 antibody included the 10 C-terminal amino acids of human Ab starting at residue #33 (   33   GLMVGGVVIA   42 , referred to as Ab33-42). The immunogenic peptide C-KKKGS-PADRE-Ab31-40 used for anti-40 antibody production comprised the 10 C-terminal amino acids of human Ab starting at residue #31 (   31   IIGLMVGGVV   40 , referred to as Ab31-40). The PADRE sequence (pan HLA-DR epitope; sequence: aK(X)VAAWTLKAAa, where X ¼ L-cyclohexylalanine and a ¼ D-amino acid) can bind to C57BL/6 mouse MHC-II molecules (H-2 b haplotype) and elicit the T helper type 2 response. 29, 30 Additional details on their synthesis, purification and integrity analysis are described in Supplementary Information. Both peptides were coupled via their N-terminal cysteine residue to maleimide-activated mcBSA (#77607 Pierce Conjugation Kit, Rockford, IL, USA) for immunization.
Generation of antibody-producing hybridoma clones.
Experimental protocols requiring the use of mice were reviewed by the Institutional Animal Ethics Committee (Sysdiag HT-Mab facility, Montpellier, France). The detailed description of the immunization protocol, hybridoma production with the Sp2/0Ag14 myeloma cell line and mAb purification are in Supplementary Information. Clone selection (specific reactivity toward the relevant biotinylated peptide and absence of reactivity against the other biotinylated peptide) was done by sandwich enzyme-linked immunosorbent assay based on the capture of N-terminally biotinylated Ab1-40 or Ab1-42 (AnaSpec, Fremont, CA, USA) on streptavidin-coated plaques and their detection by hybridoma supernatants and goat anti-Fc antibodies (Sigma, St Louis, MO, USA). Specific anti-40 (6H7 clone) and anti-42 (12E8 clone) antibodies were selected, amplified and purified on protein A Sepharose columns (GE Healthcare, Piscataway, NJ, USA).
X-MAP assays. All Ab peptides were purchased from AnaSpec as lyophilized powder, solubilized in dimethyl sulphoxide (2 mg ml ) and conserved at À 20 1C. Standard aliquots (2 mg ml À 1 in dimethyl sulphoxide) were prepared and stored at À 20 1C. For test reproducibility, a new aliquot was used for each experiment and was not kept after standard reconstitution in Dulbecco's modified Eagle's medium/1% foetal calf serum. Different multiplexed Cter assays, which allow the capture of peptides via their C-terminus, were designed to measure the concentration of truncated Ab peptides. Carboxylated magnetic beads from different microsphere numbers were chemically coupled with anti-40 6H7, anti-42 12E8 or IRR (irrelevant) antibodies and coupling evaluated with phycoerythrin-coupled goat anti-mouse IgGs (Jackson Immunoresearch, Suffolk, UK). For truncated peptide detection, the anti-11 7H1 and anti-17 8H5 mAbs 24 were used as detection antibodies after biotinylation (EZ-link Micro Biotinylation Kit, Pierce). Two different Cter sandwich assays were designed, based on the same bead combination (the 6H7/12E8/IRR triplex), to detect either 11-x or 17-x species (x ¼ 40 or 42) depending on the used detection antibody.
CSF Ab1-42, T-Tau and P-Tau concentrations were measured with the AlzBio3 multiplex assay (Innotest, Innogenetics, Gent, Belgium).
CSF samples. Human CSF samples from age-matched patients with AD (n ¼ 23) or MCI (n ¼ 23) and donors with normal cognition (controls, n ¼ 21) were provided by PrecisionMed (San Diego, CA, USA 31 ). The clinical protocol, consent forms and CSF registry were approved by the Western Institutional Review Board located in Washington, USA. Subjects with Mini-Mental State Examination (MMSE) score 413 to o28 signed the approved written informed consent and agreed to blood sampling by venipuncture (o90 ml blood) and CSF collection (o25 ml) by lumbar puncture every 6 months. The age at enrolment was 450 years and previous (within 2 years) brain scans excluded other pathologies as cause of dementia/memory disorder. Exclusion criteria were (1) evidence of multi-infarct dementia and drug intoxication, thyroid disease, pernicious anaemia, tertiary syphilis, chronic infections of the nervous system, normal pressure hydrocephalus, Huntington's disease, Creutzfeldt-Jakob disease, brain tumours, polypharmacy and Korsakoff's syndrome; (2) life expectancy o3 years; and (3) any contraindication to lumbar puncture, including anticoagulant therapy and subjects taking aspirin, aspirin-containing products or non-steroidal anti-inflammatory products, within 1 week from lumbar puncture. The probable AD classification was based on the NINCDS-ADRDA criteria: 32 MMSE X13 and p26; deficit in two or more areas of cognition; no consciousness disturbance; onset between 40 and 90 years, generally after the age of 65; and absence of systemic disorders or other brain disease that could account for the cognitive impairment. MCI was diagnosed based on: MMSE X21 and p28; no dementia; memory complaint; preserved general cognitive function; intact daily living activities; problems with two or less of the following activities: phone calls, meal preparation, handling money, completing chores; abnormal memory function documented by scores below the education-adjusted cutoff at the logical Memory II subscale (delayed paragraph recall) from the Wechsler Memory Scale-Revised (maximum score ¼ 25). The ADASCog 33 and Cognitive Dementia Rating-Global Score (CDR-GS 34, 35 ) scores were calculated for each participant. MMSE, ADAS-Cog and CDR sum of boxes (CDR-SB 36 ) significantly discriminated the different groups with no gender-linked differences (Table 1a) . Patients with MCI were divided as indicated in the validated interpretative guideline for the CDR-SB score, 37 with a lower cutoff (1.5 instead of 2) for the detection of very early cognitive impairment. MCI patients with CDR-SB p1.5 (MCI p1.5 group, n ¼ 9) correspond to patients with 'questionable impairment' and the MCI X2 group (n ¼ 14) to patients with 'very mild dementia' (Table 1b) . Lumbar puncture, cognitive tests and diagnosis were all performed the same day to avoid any bias between clinical evaluation and CSF sampling. All CSF samples were stored in polypropylene tubes at À 80 1C as previously described 38 until thawing for immunoassays. All CSF Ab11-x and Ab17-x measurements were performed twice in two independent experiments to ensure the reliability of the conclusions.
Statistical analyses. Statistical analyses and figures were done using the 'R/Bioconductor' statistical open source software 39 or the SAS software v9.2 (SAS Institute, Cary, NC, USA). Univariate differential analysis was performed with the more appropriate statistical test (control of the normality and homoscedasticity hypotheses). Multiple testing corrections enabled to adjust the P-value of each marker to control the false discovery rate. The Benjamini and Hochberg approach 40 was applied with the 'multi-test' package. Adjusted P-values o0.05 were considered as statistically significant. All biomarker distributions are illustrated with boxplots and medians. The accuracy of each marker and its discriminatory power was evaluated using the Receiving Operating Characteristics (ROC) analysis. ROC curves are the graphical visualization of the reciprocal relation between sensitivity (Se) and specificity (Sp) of a test for various values. In addition to univariate analysis, all markers were combined to evaluate the potential increase in sensibility and specificity using two multivariate approaches (logistic regression 41 and mROC method 42 ) . A logistic regression model was applied using biomarkers as categorical variables and the median values as cut-points. A backward selection process was considered in order to converge on the best multivariate model. 43 The Wald statistic criterion of P-value o0.05 was used to keep variables in the final statistical model. Adjusted odds ratios and their 95% confidence intervals were computed for significant variables in the final model. The mROC program is dedicated to identifying the linear combination 44 that maximizes the area under the ROC curve. 45 The equation for the underlying combination is provided and can be used as a decision rule. The DeLong's test 46 was also employed to compare several ROC curves.
Results
Antibody characterization. We produced specific anti-40 (6H7) and anti-42 (12E8) mAbs that displayed high affinity toward their corresponding synthetic peptides and exclusive specificity as no significant crossreaction toward other C-terminal truncated Ab peptides was observed by surface plasmon resonance analyses (Supplementary Table S1 ). Thus, unlike 4G8 that, as expected, interacted similarly with both N-40 and N-42 peptides with affinities in the nanomolar range, 6H7 only bound to N-40 peptides, whereas 12E8 Figure S1) .
Characterization and validation of the 6H7/12E8/IRR triplex assays. We then developed two 6H7/12E8/IRR triplex assays in which AbN-40 and AbN-42 peptides are simultaneously captured via their C-terminus by the 6H7 and 12E8 antibodies. Ab11-x or Ab17-x peptides are then detected with the 7H1 or 8H5 mAbs that were previously characterized. 24 Sandwich assays performed with all mAb combinations showed a detection limit of o10 pg ml Figure S2) . This rather high sensitivity allowed the accurate assessment of AbN-x peptides in complex media. The reproducibility of these assays was examined using supernatants from HEK293 cell lines that express wild-type AbPP (APPwt), wild-type APP and BACE1 (AbPPwt þ BACE1) or AbPP with the Swedish mutation (APPsw) and that secrete various Ab11-x and Ab17-x Abbreviations: AD, Alzheimer's disease; CTRL, controls; MCI, mild cognitive impairment; P-Tau, phosphorylated Tau; T-Tau, total Tau. The CSF biomarkers presented classical AD-like profiles with significant progressive decrease of Ab1-42 and increase of both T-Tau and P-Tau concentration in accordance with the severity of the pathology. The concentration of the Ab11-40 and Ab11-42 peptides was lower in patients with MCI than in controls. Ab17-40 level did not differ significantly in the three groups and Ab17-42 concentration was lower in the AD group. Figure S3) . Reproducibility was satisfactory for CSF Ab11-x measurements (percent coefficient of variation o20%), and slightly more variable but still acceptable for Ab17-x measurements (percent coefficient of variation between 20 and 30% for Ab17-40 and B30% for Ab17-42).
To further validate the assay specificity, we examined the ability of the multiplexed assays to discriminate between peptides differing by only one amino acid. Thus, we compared the reactivity of the 6H7/7H1 and 6H7/4G8 sandwich assays toward Ab 9-40, 10-40, 11-40, 12-40 or 13-40 peptides (Supplementary Figure S4A) Figure  S4B) . The 6H7/7H1 and 6H7/8H5 assays clearly showed a restricted specificity toward Ab11-40 and Ab17-40 peptides, respectively. Conversely, the 4G8 antibody detected all tested peptides with different sensitivities, according to the peptide sequence.
As the concentrations of truncated fragments and flAb in pathological conditions are unknown and could vary during the disease course, we examined whether high levels of flAb could influence the detection of truncated fragments in the two assays. High concentrations of Ab1-40 or Ab1-42 (4100-fold above the affinity constant for the truncated fragments) did not significantly affect Ab11-x or Ab17-x detection, respectively (Supplementary Figure S5) . We therefore conclude that, in these experimental conditions, the binding capacity of the beads remains sufficient to preclude any technical bias, thereby validating the use of the 6H7/12E8/IRR triplex assays for the detection and quantification of N-truncated Ab peptides in human CSF samples. Abbreviations: CI, confidence interval; MCI, mild cognitive impairment; T-Tau, total Tau. Variables were discretized using the median values as cut-points. The significant variables retained in the backward elimination model were T-Tau, Ab11-40 and Ab17-40. The model had a good fitness as estimated by the Hosmer-Lemeshow test (P40.05).
Figure 1
The Ab1-42/P-Tau and Ab1-42/T-Tau ratios do not allow discriminating between the mild cognitive impairment (MCI) p1.5 group and controls (CTRL). P-Tau, phosphorylated Tau; T-Tau, total Tau. The Ab17-40/Ab11-40 ratio significantly differentiates the MCI p1.5 group from controls. The symbol '-' indicates P40.05; *Po0.05; **Po0.01.
Quantification of Ab11-x and Ab17-x peptides in CSF allows MCI detection at early stages. We then quantified the concentration of Ab11-40, Ab11-42, Ab17-40 and Ab17-42 peptides using the two Cter 6H7/12E8/IRR triplex assays and the concentration of Ab1-42, T-Tau and P-Tau with the AlzBio3 assay in CSF samples from patients with AD or MCI (n ¼ 23 per group) and controls (n ¼ 21; Table 2a ). As previously reported, 10, 47 Ab1-42 was significantly reduced whereas T-Tau and P-Tau concentrations were significantly higher in CSF samples from patients with MCI than from controls (Po0.05). These differences were further exacerbated at the AD stage (Po0.001). Ab11-40 and Ab11-42 concentrations were significantly lower in patients with MCI than in controls (Po0.01), whereas no significant difference was observed in Ab17-x levels in the three groups, but for Ab17-42 between controls and AD (Po0.05). Ab11-40 and Ab11-42 peptides discriminated more efficiently patients with MCI from controls, even when compared with the classical biomarkers Ab1-42, T-Tau and P-Tau (Table 2b ). Analysis of different marker combinations for discriminating patients with MCI from controls using the mROC program (Table 3) and logistic regression analysis (Table 4) indicated that the combination of Ab11-40, Ab17-40 and T-Tau allowed the best evaluation of the MCI risk (multivariate adjusted odds ratio: 15.30, Po0.05 for each biomarker). Accordingly, a person with a CSF Ab11-40 level o147.6 pg ml À 1 was 18.8 times more at risk to have MCI. This result was strengthened by the mROC approach, which confirmed that, compared with the reference Ab1-42, T-Tau and P-Tau combination (sensitivity 60.87%; specificity 66.67%; area under the ROC curve 0.727), the Ab11-40, Ab17-40 and T-Tau combination better discriminated patients with MCI from controls (sensitivity 73.91%; specificity 95.24%; area under the ROC curve 0.890; Table 3 and Supplementary Figure S6 ).
Quantification of Ab11-x and Ab17-x peptides discriminate patients with MCI at different stages of severity. MCI is a complex concept that covers various stages characterized by distinct cognitive dysfunctions. Thus, to further investigate the potential interest of the measurements of N-truncated Ab peptides for MCI diagnosis, we classified patients with MCI in two subgroups (MCI p1.5 and MCI X2) based on their CDR-SB score, because CDR-SB reliably measures AD clinical and pathological progression. 37, 48, 49 Ab1-42, T-Tau and P-Tau could not significantly discriminate patients with very early MCI (MCI p1.5) from controls (Supplementary Figure S7A) . Conversely, Ab11-40 concentration was significantly lower (fold median ¼ 0.78; Po0.01) and Ab17-x concentration tended to be higher (not significant) in CSF samples from patients with MCI p1.5 than in controls (Supplementary Figures S7B and S7C) . Accordingly, the Ab17-40/Ab11-40 ratio was significantly increased in the MCI p1.5 group in comparison with controls ( Figure 1 , fold median ¼ 2.07; Po0.01), whereas the classical Ab1-42/P-Tau and Ab1-42/T-Tau ratios, which have potential predictive value, could not differentiate controls from patients with MCI p1.5 ( Figure 1) . Noteworthy, the Ab17-42/Ab11-42 ratio also discriminated, although with lower significance, the MCI p1.5 group from controls ( Figure 1b) . When analysing patients with very early cognitive impairment, the increase of the Ab17-40/Ab11-40 ratio becomes more significant when the used CDR-SB cutoff decreases, highlighting the potential value of this ratio for describing very early cognitive impairment, or categorizing the MCI status (Supplementary Figure S8) .
Discussion
This study highlights for the first time the potential diagnostic value of the CSF concentration of Ab11-40, Ab11-42, Ab17-40 and Ab17-42 peptides for early AD detection and MCI characterization. These results are based on new sensitive multiplexed assays that were validated using different synthetic peptides and cell supernatants, before use in human CSF samples. We also show that the Ab11-40, Ab17-40 and T-Tau combination might better discriminate patients with MCI from controls than the currently used Ab1-42, T-Tau and P-Tau combination.
The results obtained with these multiplexed assays in controls and patients with MCI or AD highlight several important points. First, the AbN-40 and AbN-42 diagnostic performances in controls and patients with MCI are not significantly different. This suggests that the subsequent cleavages of b'-secretase (C89) and a-secretase (C83)-derived AbPP fragments by g-secretase leading to Ab11-x or Ab17-x peptides, respectively, does not account for the setting of early proteolytic alterations responsible for the generation of N-terminally truncated Ab fragments during early MCI stages.
Second, the Ab11-x levels in CSF samples from MCI patients were lower than in controls. Several previous studies demonstrated that BACE1 b'-cleavage between the Y10 and E11 residues of Ab is dependent on the BACE1 activity level. Ab11-x concentration is supposed to be lower in physiological conditions 50 than in AD 24,51-56 because BACE1 is upregulated in AD-affected brains, and could be associated with hippocampal atrophy. 57 The apparent CSF reduction of Ab11-x peptides in MCI could reflect their high hydrophobicity and aggregative properties, thus explaining their presence in plaques 19, 58 and their reduced presence in CSF samples as previously described for pathogenic flAb42. Alternatively, one cannot exclude the possibility of a modification of BACE1 activity/affinity toward other cleavage sites as previously suggested 59, 60 that would favour breakdown at the b-site cleavage rather than at the b' one. A proteolytic shift between b and b' sites of cleavages was recently highlighted by the discovery of a new AbPP mutation at the E11 residue (E682K) in a Belgian patient with early-onset AD. This mutation prevents b'-cleavage and thus simultaneously decreases the production of C89 fragments and Ab11-x peptides, while increasing that of C99 fragments and Ab1-x peptides. 61 This finding suggests that elevated Ab11-x concentration in CSF samples represents a protective signature because AbPP cleavage at the b'-site has been considered nonamyloidogenic. 61 It would be interesting to evaluate the CSF concentration of Ab11-x in these patients and in patients with other APP mutations, such as the A673T mutation that has protective effect against AD by affecting directly the b-cleavage of AbPP by BACE1 and reducing Ab1-x secretion. 62 Third, Ab17-x measurements, especially Ab17-40, are of interest for discriminating between controls and patients with MCI, as shown by the mROC and logistic regression analyses. This may be explained by the heterogeneity of the MCI group. Indeed, this population could be divided in two subgroups (MCI p1.5 and MCI X2, based on their CDR-SB score). In our study, despite the low number of patients, the CDR-SB classification fitted very well with the scores of other cognitive tests, such as the MMSE or ADAS-cog (see Table 1b ), thus strengthening our results. The Ab1-42, T-Tau and P-Tau biomarkers and the Ab1-42/T-Tau and Ab1-42/P-Tau ratios, which were reported to have prognostic values, 10, 11, [63] [64] [65] could not discriminate controls from the MCI p1.5 group. Conversely, the Ab17-40/Ab11-40 ratio was significantly higher in the MCI p1.5 group than in controls. Despite a lower discriminating value, the Ab17-42/Ab11-42 ratio allowed the identification of this subgroup as well. To our knowledge, this is the first report in which the modulation of a-secretase-derived products could be detected during the very first steps of AD. Indeed, previous studies aimed at detecting the CSF concentrations of secreted APPa, which derives from a-secretase cleavage of AbPP, did not find any significant variation in its level. 28, 66 This may indicate that the first steps of AD could be characterized by an increase of the CSF concentration of Ab17-x peptides, which are toxic component of diffuse amyloid deposits, [67] [68] [69] probably because of a lack of degradation or modulation of their aggregation, rather than by an increase or decrease of a-secretase activity.
In conclusion, our results show differential CSF concentrations of b'-and a-secretase-derived peptides during AD progression and suggest the possible role of Ab11-x and Ab17-x peptides in the first steps of AD, highlighting key physiological aspects of the pathology. The clinical interest of Ab11-x and Ab17-x peptides as new biomarkers for improving MCI detection and characterization and as a consequence the stratification of MCI patients has to be further validated in longitudinal clinical studies, especially for delineating the outcome of the different MCI subpopulations. Our study adds new candidates to the cohort of Ab-related fragments that could contribute to the aetiology of early-stage AD. Overall, it indicates that conclusions based on the monitoring of flAb alone or on the results of immunological assays using antibodies that interact nonspecifically with all AbN-40/42 species should be reconsidered.
